ACAD
Price
$19.95
Change
+$0.06 (+0.30%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
3.54B
40 days until earnings call
Intraday BUY SELL Signals
DNLI
Price
$20.01
Change
-$0.52 (-2.53%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
3.35B
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACAD vs DNLI

ACAD vs DNLI Comparison Chart in %
View a ticker or compare two or three
VS
ACAD vs. DNLI commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and DNLI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ACAD vs DNLI: Fundamental Ratings
ACAD
DNLI
OUTLOOK RATING
1..100
5257
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
90
Overvalued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
2998
PRICE GROWTH RATING
1..100
8258
P/E GROWTH RATING
1..100
8699
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (62) in the Biotechnology industry is in the same range as DNLI (90). This means that ACAD’s stock grew similarly to DNLI’s over the last 12 months.

ACAD's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as DNLI (100). This means that ACAD’s stock grew similarly to DNLI’s over the last 12 months.

ACAD's SMR Rating (29) in the Biotechnology industry is significantly better than the same rating for DNLI (98). This means that ACAD’s stock grew significantly faster than DNLI’s over the last 12 months.

DNLI's Price Growth Rating (58) in the Biotechnology industry is in the same range as ACAD (82). This means that DNLI’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's P/E Growth Rating (86) in the Biotechnology industry is in the same range as DNLI (99). This means that ACAD’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 5 days ago
63%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 22 days ago
77%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
80%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (ACAD: $19.89 vs. DNLI: $20.53)
Brand notoriety: ACAD and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 141% vs. DNLI: 110%
Market capitalization -- ACAD: $3.54B vs. DNLI: $3.35B
ACAD [@Biotechnology] is valued at $3.54B. DNLI’s [@Biotechnology] market capitalization is $3.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green while DNLI’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 6 bearish.
  • DNLI’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -10.32% price change this week, while DNLI (@Biotechnology) price change was +0.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.58%. For the same industry, the average monthly price growth was -14.40%, and the average quarterly price growth was -1.79%.

Reported Earning Dates

ACAD is expected to report earnings on Nov 11, 2026.

DNLI is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ACAD
Daily Signal:
Gain/Loss:
DNLI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FSMD49.630.46
+0.94%
Fidelity Small-Mid Multifactor ETF (FSMD)
THEQ30.100.02
+0.06%
T. Rowe Price Hedged Equity ETF
HSMV35.23N/A
N/A
First Trust Horizon Managed Volatility Small/Mid ETF (HSMV)
SPSK17.37N/A
N/A
SP Funds Dow Jones Global Sukuk ETF (SPSK)
IHD7.53-0.04
-0.53%
VOYA EMERGING MARKETS HIGH Income DIVIDEND EQUITY FUND

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with CLDX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-1.29%
CLDX - ACAD
45%
Loosely correlated
-0.71%
RIGL - ACAD
43%
Loosely correlated
-2.45%
IDYA - ACAD
42%
Loosely correlated
-1.59%
DNLI - ACAD
42%
Loosely correlated
-0.68%
MGTX - ACAD
40%
Loosely correlated
-3.09%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with VIR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.68%
VIR - DNLI
52%
Loosely correlated
+0.98%
VCYT - DNLI
50%
Loosely correlated
-4.02%
BCYC - DNLI
50%
Loosely correlated
-3.26%
EDIT - DNLI
49%
Loosely correlated
-1.95%
BEAM - DNLI
48%
Loosely correlated
-0.25%
More